At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 9, 2026 at 09:30 ET
Oncolytics Biotech announced translational data from a Phase 1b/2 trial of pelareorep in heavily pretreated relapsed/refractory multiple myeloma, to be presented at the ASH annual meeting. The data show immune activation and direct tumor effects, but this is an early-stage, non-regulatory update with no new clinical endpoints or financial guidance.
- Translational data from Phase 1b/2 trial in relapsed/refractory multiple myeloma patients with median 4 prior lines of therapy
- Data show enhanced antigen-presenting activity, increased apoptotic signaling, and expansion of CD8 effector memory T cells
- Clinical responders had greater CD8 EM T cell expansion and lower T cell exhaustion vs non-responders
- Data to be presented at ASH annual meeting on December 12, 2026 (abstract #2183)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access